Abstract
Retinoic acid receptors (RARs) are ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth, differentiation, survival and death. Due to their regulatory potential, these nuclear receptors (NRs) are major drug targets for a variety of pathologies, including cancer and metabolic diseases. A large amount of RAR- and RXR-selective ligands, ranging from (partial) agonists to antagonists and inverse agonists, have been designed and the corresponding structural and functional analyses have provided deep insight into the molecular basis of ligand action. Ligands regulate, via allosteric conformational changes, the ability of these NRs to interact with different sets of coregulators, which in turn recruit enzymatically active complexes/machineries. Here, we describe strategies in the design of selective RXR and RAR modulators and review the structural mechanisms by which the diverse pharmacological classes of compounds modulate receptor functions. Finally, we discuss the perspectives for retinoid- and rexinoid-based therapies.
Keywords: Retinoic acid receptors, retinoid X receptors, agonists and antagonists action, ligand design, selective ligands, structure-function relationship, thee-dimensional structure, therapeutic potential, antagonists rexinoid apoptosis, retinoid- and rexinoid-based therapies
Current Topics in Medicinal Chemistry
Title: Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
Volume: 12 Issue: 6
Author(s): Albane le Maire, Susana Alvarez, Pattabhiraman Shankaranarayanan, Angel R de Lera, William Bourguet and Hinrich Gronemeyer
Affiliation:
Keywords: Retinoic acid receptors, retinoid X receptors, agonists and antagonists action, ligand design, selective ligands, structure-function relationship, thee-dimensional structure, therapeutic potential, antagonists rexinoid apoptosis, retinoid- and rexinoid-based therapies
Abstract: Retinoic acid receptors (RARs) are ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth, differentiation, survival and death. Due to their regulatory potential, these nuclear receptors (NRs) are major drug targets for a variety of pathologies, including cancer and metabolic diseases. A large amount of RAR- and RXR-selective ligands, ranging from (partial) agonists to antagonists and inverse agonists, have been designed and the corresponding structural and functional analyses have provided deep insight into the molecular basis of ligand action. Ligands regulate, via allosteric conformational changes, the ability of these NRs to interact with different sets of coregulators, which in turn recruit enzymatically active complexes/machineries. Here, we describe strategies in the design of selective RXR and RAR modulators and review the structural mechanisms by which the diverse pharmacological classes of compounds modulate receptor functions. Finally, we discuss the perspectives for retinoid- and rexinoid-based therapies.
Export Options
About this article
Cite this article as:
le Maire Albane, Alvarez Susana, Shankaranarayanan Pattabhiraman, R de Lera Angel, Bourguet William and Gronemeyer Hinrich, Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators, Current Topics in Medicinal Chemistry 2012; 12 (6) . https://dx.doi.org/10.2174/156802612799436687
DOI https://dx.doi.org/10.2174/156802612799436687 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Formation of Five- and Six-Membered α,β-Unsaturated Lactones through Ring- Closing Metathesis of Functionalized Acrylates. Applications to Synthesis of Natural Products
Current Organic Chemistry HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies
Current Pharmaceutical Biotechnology A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity
Letters in Drug Design & Discovery The Dichloromethane Fraction of <i>Vernonia cinerea</i> Impart Pro-Apoptotic, Genotoxic, Cell Cycle Arrest, and Drug Efflux Inhibitory Effects on Human Adenocarcinoma Cells
Recent Patents on Anti-Cancer Drug Discovery Targeting Post-Ejaculation Sperm for Value-Added Contraception
Current Molecular Pharmacology In Silico Screening of Novel Inhibitors for HPV: A Rational Structure Based Approach (Docking Versus Pharmacophore Model Generation)
Letters in Drug Design & Discovery Effect of the Bioactive Fraction of Argyreia speciosa Leaves Against Gastric Ulcer and Antioxidant Defence System in Rats
Current Traditional Medicine Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Pulmonary Squamous Papilloma Complicating Recurrent Tracheal Papillomatosis
Current Respiratory Medicine Reviews Co-delivery of Plasmid DNA and Antisense Oligodeoxyribonucleotide into Human Carcinoma Cells by Cationic Liposomes
Current Pharmaceutical Biotechnology Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry